Optimizing Medical Management Post-Revascularization: A Case Review

In this activity, expert faculty give their multidisciplinary perspectives in vascular surgery and cardiology regarding recommendations for patients with peripheral artery disease (PAD) post-revascularization. These patients are at risk for further complications and may be eligible for additional therapy. Dr. Marc Bonaca and Dr. Alan Dietzek relay practice implications of the latest guidelines and data across the various agents and combinations for patients with PAD.

Because US peripheral artery disease (PAD) guidelines have not yet been updated, clinicians may not yet be familiar with the groundbreaking VOYAGER PAD study just published in May 2020 which showed that the addition of rivaroxaban to aspirin reduced risk of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes. It is critical for vascular surgeons, interventional cardiologists, and other healthcare providers who care for patients with PAD to understand the latest data to ensure that their patients receive the best possible care and mitigate further complications.